血液透析患者感染SARS-CoV-2奥密克戎变异株的结局与疫苗接种效果:一项队列研究
多中心队列研究纳入奥密克戎流行期1126例SARS-CoV-2阳性血液透析患者,其中未接种200例(18%)、首剂后56例(5%)、第二剂后433例(38%)、第三剂至少7天后437例(39%)。多数患者病程轻微,但160例(14%)住院、28例(2%)死亡。调整年龄和合并症后,两剂疫苗与住院减少39%(95%CI:2%-62%)相关,第三剂额外提供51%(95%CI:25%-69%)的住院进一步减少;在观察期开始时1265例高危患者中,两剂疫苗与感染发生率减少41%(95%CI:3%-64%)相关,第三剂无明确额外效果。
要点
- 奥密克戎流行期血液透析患者SARS-CoV-2感染后多数病程轻微,但14%住院、2%死亡。
- 两剂疫苗与住院减少39%相关,第三剂额外减少住院51%。
- 两剂疫苗与感染发生率减少41%相关,第三剂无明确额外效果。
核心结论
- 数据显示奥密克戎主导流行期透析患者接种疫苗后SARS-CoV-2感染发生率较低。
- 在感染患者中,既往接种疫苗者重症较少见,尤其是第三剂疫苗后。
研究设计与样本
- 多中心研究,在奥密克戎变异株驱动的流行期间识别所有SARS-CoV-2阳性血液透析患者。
- 感染风险采用Cox比例风险模型分析,结局按包括疫苗接种状态在内的预测变量分析。
主要发现
- 1126例SARS-CoV-2感染患者中,未接种200例(18%)、首剂后56例(5%)、第二剂后433例(38%)、第三剂至少7天后437例(39%)。
- 多数患者病程轻微,但160例(14%)住院、28例(2%)死亡。
- 调整年龄和合并症后,两剂疫苗与住院减少39%(95%CI:2%-62%)相关,第三剂额外提供51%(95%CI:25%-69%)的住院进一步减少。
- 观察期开始时1265例高危患者中,SARS-CoV-2感染211例(17%)。
- 两剂疫苗与感染发生率减少41%(95%CI:3%-64%)相关,第三剂无明确额外效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemodialysis patients are at high risk of Covid-19, though vaccination has significant efficacy in preventing and reducing the severity of infection. Little information is available on disease severity and vaccine efficacy since the dissemination of the Omicron variant. METHODS: In a multi-center study, during a period of the epidemic driven by the Omicron variant, all hemodialysis patients positive for SARS-CoV-2 were identified. Outcomes were analyzed according to predictor variables including vaccination status. Risk of infection was analyzed using a Cox proportional hazards model. RESULTS: SARS-CoV-2 infection was identified in 1126 patients including 200 (18%) unvaccinated, 56 (5%) post first dose, 433 (38%) post second dose, and 437 (39%) at least 7 days beyond their third dose. The majority of patients had a mild course but 160 (14%) were hospitalized and 28 (2%) died. In regression models adjusted for age and comorbidity, two-dose vaccination was associated with a 39% (95%CI: 2%-62%) reduction in admissions, but third doses provided additional protection, with a 51% (95%CI: 25%-69%) further reduction in admissions. Among 1265 patients at risk at the start of the observation period, SARS-CoV-2 infection was observed in 211 (17%). Two-dose vaccination was associated with a 41% (95%CI: 3%-64%) reduction in the incidence of infection, with no clear additional effect provided by third doses. CONCLUSIONS: These data demonstrate lower incidence of SARS-CoV-2 infection after vaccination in dialysis patients during an Omicron dominant period of the epidemic. Among those developing infection, severe illness was less common with prior vaccination, particularly after third vaccine doses.
引用
- Ashby DR, Caplin B, Corbett RW, et al. Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study. Nephrol Dial Transplant. 2022. PMID: 35767848. doi:10.1093/ndt/gfac209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。